Leap Executives Convert RSUs to Shares as Insider Confidence Fuels Stock Surge at Leap Therapeutics.

Insider Activity Highlights Leap’s Dual‑Track Strategy

Leap Therapeutics Inc. (NASDAQ: LPTX) has seen a flurry of insider transactions in the past week, with key executives converting a sizable batch of restricted stock units (RSUs) into common shares on March 13, 2026. The 168,750 new shares purchased by Richard Christian M and several other insiders represent a net increase of 168,750 shares in the public float—an 0.5% rise in total outstanding shares given the company’s 33.2 million‑share market cap. While modest in absolute terms, the move underscores the confidence of top management in Leap’s near‑term prospects.

What the Transaction Means for Investors

The conversion of RSUs at the prevailing market price of $0.79 suggests that executives are taking advantage of a recent price uptick—Leap’s stock closed at $0.7049 on March 15, up 39.74% over the week and 91.25% year‑to‑date. By locking in shares, insiders signal that they expect the upward trend to continue. For investors, the activity offers a double‑edged signal: on one hand, it demonstrates internal optimism; on the other, it dilutes existing shareholders slightly, as new shares enter the market. Given Leap’s negative price‑earnings ratio of –0.52 and its focus on late‑stage clinical programs, the dilution may be viewed as a strategic trade‑off for accelerating commercialization and funding future trials.

Richard Christian M: A Pattern of Forward‑Looking Grants

Richard Christian M’s transaction history reveals a consistent pattern of RSU grants tied to milestone‑based equity plans. In December 2025, he received 94,050 RSUs under the 2025 Equity Incentive Plan, which vested immediately and were settled in March 2026. His simultaneous purchase of 74,700 and 94,050 common shares on the same day indicates a desire to convert performance‑based equity into liquid holdings. Over the past year, he has repeatedly exercised RSU conversions, suggesting a preference for liquidity as the company’s valuation improves. Investors may interpret this as a sign that he believes Leap’s stock will appreciate further, prompting early conversion before potential upside is capped by future performance restrictions.

Company‑Wide Insider Momentum

Leap’s insiders, including Dietz Thomas John, Mirabelli Christopher, and Oei Khing Djien, mirrored M’s activity, collectively buying 169,000 shares and selling all RSUs in the same period. This coordinated buying spree coincides with a 109% social‑media buzz and a +6 sentiment score—a positive, albeit modest, reception on platforms like Reddit and X/Twitter. The heightened buzz, combined with the stock’s weekly surge, indicates that the broader market is paying close attention to Leap’s dual focus on cancer therapeutics and a privacy‑technology platform centered on Zcash.

Outlook for Leap Therapeutics

Leap’s dual‑track strategy—advancing the sirexatamab Phase 2 program while expanding its digital‑asset portfolio—appears to be paying off in the short term, as reflected by the stock’s recent gains and insider confidence. For investors, the key will be whether the company can translate clinical milestones into commercial success and monetize its Zcash holdings without compromising its R&D pipeline. The recent insider conversions provide a subtle endorsement, but the negative earnings ratio and heavy reliance on unrealised digital‑asset gains highlight the importance of monitoring revenue generation and regulatory approvals in the coming quarters.